Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Short Interest Up 383.3% in March

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 11,600 shares, a growth of 383.3% from the February 29th total of 2,400 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average daily volume of 19,000 shares, the short-interest ratio is currently 0.6 days.

Institutional Trading of Finch Therapeutics Group

A number of large investors have recently modified their holdings of FNCH. BlackRock Inc. increased its stake in shares of Finch Therapeutics Group by 2.3% during the first quarter. BlackRock Inc. now owns 404,931 shares of the company’s stock worth $2,038,000 after buying an additional 9,149 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Finch Therapeutics Group by 19.4% in the 1st quarter. Renaissance Technologies LLC now owns 45,000 shares of the company’s stock valued at $226,000 after purchasing an additional 7,314 shares during the last quarter. Millennium Management LLC purchased a new position in Finch Therapeutics Group during the 2nd quarter worth approximately $259,000. Goldman Sachs Group Inc. acquired a new position in Finch Therapeutics Group during the second quarter worth approximately $98,000. Finally, MSD Partners L.P. purchased a new position in Finch Therapeutics Group during the 3rd quarter worth $26,000. Hedge funds and other institutional investors own 21.77% of the company’s stock.

Finch Therapeutics Group Stock Performance

NASDAQ:FNCH opened at $2.60 on Friday. The stock has a 50 day moving average price of $2.65 and a 200 day moving average price of $3.61. The stock has a market cap of $4.19 million, a PE ratio of -0.05 and a beta of 0.45. Finch Therapeutics Group has a one year low of $2.19 and a one year high of $16.74.

Finch Therapeutics Group (NASDAQ:FNCH) last posted its earnings results on Monday, March 25th. The company reported ($1.89) EPS for the quarter.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease.